Current and Resolved Drug Shortages and Discontinuations Reported to FDA
Report a Drug Shortage |
FAQ |
Background Info |
Get Email Alerts |
Download Current Drug Shortages |
Contact Us
Start Over | Back to Search Results
Amoxicillin Powder, For Suspension
Status: Currently in Shortage
»Date first posted:
10/28/2022
»Therapeutic Categories: Anti-Infective; Pediatric
Aurobindo Pharma USA (Revised 05/15/2024)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| Powder, For Suspension, 125 mg/5 mL (NDC 65862-706-01) | Available | ||
| Powder, For Suspension, 200 mg/5 mL (NDC 65862-070-01) | Available | ||
| Powder, For Suspension, 250 mg/5 mL (NDC 65862-707-01) | Available | ||
| Powder, For Suspension, 400 mg/5 mL (NDC 65862-071-01) | Available | ||
| Powder, For Suspension, 125 mg/5 mL (NDC 65862-706-55) | Available | ||
| Powder, For Suspension, 125 mg/5 mL (NDC 65862-706-80) | Available | ||
| Powder, For Suspension, 200 mg/5 mL (NDC 65862-070-50) | Available | ||
| Powder, For Suspension, 200 mg/5 mL (NDC 65862-070-75) | Available | ||
| Powder, For Suspension, 250 mg/5 mL (NDC 65862-707-55) | Available | ||
| Powder, For Suspension, 250 mg/5 mL (NDC 65862-707-80) | Available | ||
| Powder, For Suspension, 400 mg/5 mL (NDC 65862-071-50) | Available | ||
| Powder, For Suspension, 400 mg/5 mL (NDC 65862-071-75) | Available |
Hikma Pharmaceuticals USA, Inc. (Reverified 11/25/2024)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| Powder, For Suspension, 125 mg/5 mL (NDC 0143-9888-15) | Available | ||
| Powder, For Suspension, 125 mg/5 mL (NDC 0143-9888-80) | Available | ||
| Powder, For Suspension, 200 mg/5 mL (NDC 0143-9886-50) | Available | ||
| Powder, For Suspension, 200 mg/5 mL (NDC 0143-9886-75) | Available | ||
| Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 0143-9889-15) | Available | ||
| Powder, For Suspension, 250 mg/5 mL (NDC 0143-9889-80) | Available | ||
| Powder, For Suspension, 400 mg/5 mL (NDC 0143-9887-50) | Available | ||
| Powder, For Suspension, 400 mg/5 mL (NDC 0143-9887-75) | Available | ||
| Powder, For Suspension, 125 mg/5 mL (NDC 0143-9888-01) | Available | ||
| Powder, For Suspension, 200 mg/5 mL (NDC 0143-9886-01) | Available | ||
| Powder, For Suspension, 250 mg/5 mL (NDC 0143-9889-01) | Available | ||
| Powder, For Suspension, 400 mg/5 mL (NDC 0143-9887-01) | Available |
Sandoz Inc. (Reverified 11/22/2024)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| Powder, For Suspension, 125 mg/5 mL (NDC 0781-6039-46) | Available | ||
| Powder, For Suspension, 125 mg/5 mL (NDC 0781-6039-55) | Available | ||
| Powder, For Suspension, 125 mg/5 mL (NDC 0781-6039-58) | Available | ||
| Powder, For Suspension, 200 mg/5 mL (NDC 0781-6156-46) | Available | ||
| Powder, For Suspension, 200 mg/5 mL (NDC 0781-6156-52) | Available | ||
| Powder, For Suspension, 200 mg/5 mL (NDC 0781-6156-57) | Limited Availability | Demand increase for the drug | |
| Powder, For Suspension, 400 mg/5 mL (NDC 0781-6157-46) | Limited Availability | Demand increase for the drug | |
| Powder, For Suspension, 400 mg/5 mL (NDC 0781-6157-52) | Limited Availability | Demand increase for the drug | |
| Powder, For Suspension, 400 mg/5 mL (NDC 0781-6157-57) | Limited Availability | Demand increase for the drug | |
| Powder, For Suspension, 250 mg/5 mL (NDC 0781-6041-46) | Limited Availability | Demand increase for the drug | |
| Powder, For Suspension, 250 mg/5 mL (NDC 0781-6041-55) | Available | ||
| Powder, For Suspension, 250 mg/5 mL (NDC 0781-6041-58) | Limited Availability | Demand increase for the drug |
Teva Pharmaceuticals USA, Inc. (Revised 10/15/2024)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| Amoxicillin for Oral Suspension, USP, Powder, For Suspension, 250 mg/5 mL (NDC 0093-4155-73) | Available | Estimated recovery November 2024 | |
| Amoxicillin for Oral Suspension, USP, Powder, For Suspension, 250 mg/5 mL (NDC 0093-4155-80) | Limited Availability | Estimated recovery October 2024 | Demand increase for the drug |
| Amoxicillin for Oral Suspension, USP, Powder, For Suspension, 250 mg/5 mL (NDC 0093-4155-79) | Available | Estimated recovery January 2025 | |
| Amoxicillin for Oral Suspension, USP, Powder, For Suspension, 200 mg/5 mL (NDC 0093-4160-73) | Available | ||
| Amoxicillin for Oral Suspension, USP, Powder, For Suspension, 200 mg/5 mL (NDC 0093-4160-76) | Available | ||
| Amoxicillin for Oral Suspension, USP, Powder, For Suspension, 200 mg/5 mL (NDC 0093-4160-78) | Available | Estimated recovery January 2025 | |
| Amoxicillin for Oral Suspension, USP, Powder, For Suspension, 400 mg/5 mL (NDC 0093-4161-73) | Limited Availability | Estimated recovery December 2024 | Demand increase for the drug |
| Amoxicillin for Oral Suspension, USP, Powder, For Suspension, 400 mg/5 mL (NDC 0093-4161-76) | Available | ||
| Amoxicillin for Oral Suspension, USP, Powder, For Suspension, 400 mg/5 mL (NDC 0093-4161-78) | Limited Availability | Estimated recovery December 2024 | Demand increase for the drug |